Insights from Drug Checking Programs: Practicing Bootstrap Public Health Whilst Tailoring to Local Drug User Needs.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Drug Users* ; COVID-19*/epidemiology ; Drug Overdose*/epidemiology ; Drug Overdose*/prevention & control ; Substance-Related Disorders*/epidemiology; Humans ; Public Health ; Pandemics/prevention & control ; Harm Reduction

The year 2021 was the most deadly year for overdose deaths in the USA and Canada. The stress and social isolation stemming from the COVID-19 pandemic coupled with a flood of fentanyl into local drug markets created conditions in which people who use drugs were more susceptible to accidental overdose. Within territorial, state, and local policy communities, there have been longstanding efforts to reduce morbidity and mortality within this population; however, the current overdose crisis clearly indicates an urgent need for additional, easily accessible, and innovative services. Street-based drug testing programs allow individuals to learn the composition of their substances prior to use, averting unintended overdoses while also creating low threshold opportunities for individuals to connect to other harm reduction services, including substance use treatment programs. We sought to capture perspectives from service providers to document best practices around fielding community-based drug testing programs, including optimizing their position within a constellation of other harm reduction services to best serve local communities. We conducted 11 in-depth interviews from June to November 2022 via Zoom with harm reduction service providers to explore barriers and facilitators around the implementation of drug checking programs, the potential for integration with other health promotion services, and best practices for sustaining these programs, taking the local community and policy landscape into account. Interviews lasted 45-60 min and were recorded and transcribed. Thematic analysis was used to reduce the data, and transcripts were discussed by a team of trained analysts. Several key themes emerged from our interviews: (1) the instability of drug markets amid an inconsistent and dangerous drug supply; (2) implementing drug checking services in dynamic environments in response to the rapidly changing needs of local communities; (3) training and ongoing capacity building needed to create sustainable programs; and (4) the potential for integrating drug checking programs into other services. There are opportunities for this service to make a difference in overdose deaths as the contours of the drug market itself have changed over time, but a number of challenges remain to implement them effectively and sustain the service over time. Drug checking itself represents a paradox within the larger policy context, putting the sustainability of these programs at risk and challenging the potential to scale these programs as the overdose epidemic worsens.

Int J Drug Policy. 2021 Nov;97:103409. (PMID: 34392112)
Ir J Med Sci. 2022 Aug;191(4):1701-1710. (PMID: 34545479)
Am J Psychiatry. 2022 Feb;179(2):166-169. (PMID: 35105165)
Intern Med J. 2020 Apr;50(4):395-402. (PMID: 31908122)
Drug Alcohol Depend. 2021 Nov 1;228:108976. (PMID: 34536717)
Harm Reduct J. 2022 Feb 4;19(1):9. (PMID: 35120531)
Int J Drug Policy. 2017 Aug;46:146-155. (PMID: 28735775)
Int J Drug Policy. 2021 Apr;90:102731. (PMID: 32331859)
J Psychoactive Drugs. 2023 Jan-Mar;55(1):85-93. (PMID: 35060837)
Int J Drug Policy. 2021 Sep;95:103270. (PMID: 33972157)
BMC Public Health. 2021 Jun 16;21(1):1156. (PMID: 34134698)
Behav Sci (Basel). 2020 Jul 25;10(8):. (PMID: 32722508)
Eur Addict Res. 2021;27(1):25-32. (PMID: 32535605)
Drug Alcohol Depend. 2018 Apr 1;185:248-252. (PMID: 29475198)
Int J Drug Policy. 2017 Aug;46:107-111. (PMID: 28735776)
Drug Alcohol Depend. 2020 Mar 1;208:107779. (PMID: 31931266)
Harm Reduct J. 2022 Mar 29;19(1):33. (PMID: 35351160)
J Pharm Biomed Anal. 2021 Sep 10;204:114270. (PMID: 34332310)
Harm Reduct J. 2019 Jun 24;16(1):39. (PMID: 31234942)
Health Place. 2020 Jan;61:102245. (PMID: 31740126)
Addiction. 2022 May;117(5):1200-1202. (PMID: 35373482)
Int J Ment Health Addict. 2022 Oct 10;:1-19. (PMID: 36248265)
Drug Alcohol Depend. 2022 May 1;234:109425. (PMID: 35344879)
JAMA Psychiatry. 2022 Apr 1;79(4):379-381. (PMID: 35234815)
Drug Alcohol Depend. 2019 Jan 1;194:527-532. (PMID: 30551090)
Int J Drug Policy. 2018 Nov;61:1-6. (PMID: 30290363)
Int J Drug Policy. 2020 Mar;77:102661. (PMID: 31951925)
Am J Public Health. 2021 Jul;111(7):1284-1291. (PMID: 33856885)
Int J Environ Res Public Health. 2022 Sep 22;19(19):. (PMID: 36231262)
Int J Drug Policy. 2022 Jun;104:103676. (PMID: 35382948)
Int J Drug Policy. 2021 Apr;90:103065. (PMID: 33333419)
Drug Alcohol Depend. 2020 Jul 1;212:108006. (PMID: 32438280)
Int J Drug Policy. 2021 Aug;94:103196. (PMID: 33713964)
Drug Alcohol Depend. 2019 Dec 1;205:107589. (PMID: 31605958)
Harm Reduct J. 2018 May 16;15(1):26. (PMID: 29769132)
Int J Environ Res Public Health. 2022 Feb 16;19(4):. (PMID: 35206421)
Int J Drug Policy. 2019 Sep;71:125-132. (PMID: 31336258)
Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):224-233. (PMID: 29911818)
Int J Drug Policy. 2019 May;67:102-107. (PMID: 30541674)
Drug Alcohol Depend. 2022 Apr 1;233:109380. (PMID: 35247724)
CMAJ. 2018 Aug 7;190(31):E921-E922. (PMID: 30087127)
Science. 2018 Sep 21;361(6408):. (PMID: 30237320)
Curr Opin Psychiatry. 2020 Jul;33(4):301-305. (PMID: 32187173)
Harm Reduct J. 2018 Sep 10;15(1):46. (PMID: 30200991)
Int J Drug Policy. 2022 Sep;107:103781. (PMID: 35803177)
Int J Drug Policy. 2019 Jan;63:122-128. (PMID: 30292493)
J Viral Hepat. 2023 Feb;30(2):160-171. (PMID: 36461705)
Int J Drug Policy. 2018 Dec;62:59-66. (PMID: 30359874)
Harm Reduct J. 2020 Jan 28;17(1):9. (PMID: 32204713)
Harm Reduct J. 2021 Oct 13;18(1):104. (PMID: 34645480)
Harm Reduct J. 2018 Feb 08;15(1):7. (PMID: 29422052)
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1740-1746. (PMID: 34914673)
Int J Drug Policy. 2019 Jan;63:18-22. (PMID: 30468971)
Int J Drug Policy. 2019 Sep;71:183-188. (PMID: 30718120)
Drug Alcohol Rev. 2019 Feb;38(2):131-150. (PMID: 30785229)
Harm Reduct J. 2018 Apr 6;15(1):19. (PMID: 29625621)
Addiction. 2022 Mar;117(3):532-544. (PMID: 34729849)
Harm Reduct J. 2020 May 12;17(1):29. (PMID: 32398090)
Drug Alcohol Rev. 2022 Feb;41(2):410-418. (PMID: 34347332)
Am J Drug Alcohol Abuse. 2020 Jul 3;46(4):506-511. (PMID: 31983241)
Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350. (PMID: 33965972)
Drug Alcohol Depend. 2022 May 1;234:109398. (PMID: 35370014)
Exp Clin Psychopharmacol. 2021 Jun;29(3):229-235. (PMID: 33600199)
Drug Alcohol Rev. 2020 Jan;39(1):98-102. (PMID: 31746056)
Harm Reduct J. 2017 Jul 31;14(1):52. (PMID: 28760153)

P30 MH062246 United States MH NIMH NIH HHS; R01 DA054190 United States DA NIDA NIH HHS

Keywords: North America; community-based; drug checking; fentanyl; harm reduction; substance use

Date Created: 20230610 Date Completed: 20230612 Latest Revision: 20241031

20241031

PMC10252652

10.3390/ijerph20115999

37297603